Gene: SATB2

23314
GLSS
SATB homeobox 2
protein-coding
2q33.1
Ensembl:ENSG00000119042 MIM:608148 Vega:OTTHUMG00000132767 UniprotKB:Q9UPW6
NG_016976.1
PubMed
0   ANCO-SNPs
ND
2   
NA (AD)  NA (ND)   (Frontal_Cortex)
5.756e-1 (AD)  6.636e-1 (ND)

DNA Methylation

Probe Locus(GRCh37) Gene Region p-val Trait PubMed ID
cg14879574chr2:200136686SATB23'UTR2.193e-4Alcohol use disorders26763658

Gene Expression in Different Tissues

Temporal and Spatial Expressions (BrainSpan)

Footnote:
SC: sub-cortical regions; SM: sensory-motor regions; FC: frontal cortex; and TP: temporal-parietal cortex
ST1: fetal (13 - 26 postconception weeks), ST2: early infancy to late childhood (4 months to 11 years), and ST3: adolescence to adulthood (13 - 23 years)
The bar shown representes average value of the expressions.

Top Co-expressed Genes in Brain-Frontal Cortex (BA9) (GTEx v7)

Top 10 positively co-expressed genes

Gene Symbol Pearson Correlation Coefficient
CHRM30.955
THRB0.945
KIAA1549L0.941
GPR220.941
EPHA40.94
SV2B0.94
ZNF385B0.94
KALRN0.938
GABBR20.937
DLGAP10.937

Top 10 negatively co-expressed genes

Gene Symbol Pearson Correlation Coefficient
ACAP1-0.578
HEY2-0.555
MDFI-0.536
COPZ2-0.52
MYL3-0.518
LRAT-0.517
ARHGEF5-0.516
RAB13-0.513
SNHG18-0.503
FAM89A-0.501

Drugs/Compounds

    There is no DrugBank record for this gene !

ID Drug Name Action PubMed
C0297902,2',3',4,4',5-hexachlorobiphenyl"[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in increased expression of SATB2 mRNA"25510870
C5112952,2',4,4'-tetrabromodiphenyl ether"2,2',4,4'-tetrabromodiphenyl ether results in decreased expression of SATB2 mRNA"21394737
C0817662,4,4'-trichlorobiphenyl"[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in increased expression of SATB2 mRNA"25510870
C0140242,4,5,2',4',5'-hexachlorobiphenyl"[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in increased expression of SATB2 mRNA"25510870
C0098282,4,5,2',5'-pentachlorobiphenyl"[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in increased expression of SATB2 mRNA"25510870
C0094072,5,2',5'-tetrachlorobiphenyl"[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in increased expression of SATB2 mRNA"25510870
C4591794-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide"[NOG protein co-treated with mercuric bromide co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of SATB2 mRNA"27188386
C4591794-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide"[NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of SATB2 mRNA"27188386
C4591794-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide"[NOG protein co-treated with Valproic Acid co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SATB2 mRNA"27188386
C516138(6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine"[NOG protein co-treated with mercuric bromide co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of SATB2 mRNA"27188386
C516138(6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine"[NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of SATB2 mRNA"27188386
C516138(6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine"[NOG protein co-treated with Valproic Acid co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SATB2 mRNA"27188386
D000082AcetaminophenAcetaminophen results in decreased expression of SATB2 mRNA22230336
D016604Aflatoxin B1Aflatoxin B1 affects the expression of SATB2 protein20106945
D016604Aflatoxin B1Aflatoxin B1 results in decreased methylation of SATB2 gene27153756
D000517alpha-Chlorohydrinalpha-Chlorohydrin results in decreased expression of SATB2 mRNA28522335
D018501Antirheumatic AgentsAntirheumatic Agents results in increased expression of SATB2 mRNA24449571
C006632arsenic trioxidearsenic trioxide results in decreased expression of SATB2 mRNA15761015
D001205Ascorbic Acid[Ascorbic Acid co-treated with beta-glycerophosphoric acid co-treated with Dexamethasone] results in increased expression of SATB2 mRNA26424790
D001205Ascorbic AcidEZH2 protein inhibits the reaction [[Ascorbic Acid co-treated with beta-glycerophosphoric acid co-treated with Dexamethasone] results in increased expression of SATB2 mRNA]26424790
D001564Benzo(a)pyreneBenzo(a)pyrene results in decreased expression of SATB2 mRNA20106945|2163298
D001564Benzo(a)pyreneBenzo(a)pyrene results in increased expression of SATB2 mRNA21839799
D0151237,8-Dihydro-7,8-dihydroxybenzo(a)pyrene 9,10-oxide"7,8-Dihydro-7,8-dihydroxybenzo(a)pyrene 9,10-oxide affects the expression of SATB2 mRNA"20382639
D004958EstradiolEstradiol affects the expression of SATB2 mRNA14699072
D004958Estradiol[Estradiol binds to ESR2 protein] which results in increased expression of SATB2 mRNA20404318
C031463beta-glycerophosphoric acid[Ascorbic Acid co-treated with beta-glycerophosphoric acid co-treated with Dexamethasone] results in increased expression of SATB2 mRNA26424790
C031463beta-glycerophosphoric acidEZH2 protein inhibits the reaction [[Ascorbic Acid co-treated with beta-glycerophosphoric acid co-treated with Dexamethasone] results in increased expression of SATB2 mRNA]26424790
C006780bisphenol Abisphenol A affects the methylation of SATB2 promoter27334623
C006780bisphenol A[bisphenol A co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate] affects the methylation of SATB2 promoter23359474
C006780bisphenol Abisphenol A results in decreased expression of SATB2 mRNA25181051
C006780bisphenol Abisphenol A results in increased expression of SATB2 mRNA29097150
C018475butyraldehydebutyraldehyde results in decreased expression of SATB2 mRNA26079696
D002220CarbamazepineCarbamazepine affects the expression of SATB2 mRNA25979313
D020245p-Chloromercuribenzoic Acid"[NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of SATB2 mRNA"27188386
D020245p-Chloromercuribenzoic Acidp-Chloromercuribenzoic Acid results in decreased expression of SATB2 mRNA26272509
D002857ChromiumChromium results in increased expression of SATB2 mRNA21437242
D003042Cocaine[Cocaine co-treated with FOS protein mutant form] results in increased expression of SATB2 mRNA18355967
D003042CocaineCocaine results in decreased expression of SATB2 mRNA18355967
D003375CoumestrolCoumestrol results in decreased expression of SATB2 mRNA19167446
D003471CuprizoneCuprizone results in decreased expression of SATB2 mRNA26577399
C014347decitabinedecitabine results in decreased expression of SATB2 mRNA27915011
D003907Dexamethasone[Ascorbic Acid co-treated with beta-glycerophosphoric acid co-treated with Dexamethasone] results in increased expression of SATB2 mRNA26424790
D003907DexamethasoneEZH2 protein inhibits the reaction [[Ascorbic Acid co-treated with beta-glycerophosphoric acid co-treated with Dexamethasone] results in increased expression of SATB2 mRNA]26424790
D003993Dibutyl Phthalate[bisphenol A co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate] affects the methylation of SATB2 promoter23359474
D002945Cisplatin[Cisplatin co-treated with jinfukang] results in decreased expression of SATB2 mRNA27392435
D002945CisplatinCisplatin results in decreased expression of SATB2 mRNA27392435
C000944dicrotophosdicrotophos results in increased expression of SATB2 mRNA28302478
D004051Diethylhexyl Phthalate[bisphenol A co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate] affects the methylation of SATB2 promoter23359474
D005557FormaldehydeFormaldehyde results in decreased expression of SATB2 mRNA23416264
C069837fullerene C60fullerene C60 results in decreased expression of SATB2 mRNA19167457
C412815GW 4064GW 4064 results in increased expression of SATB2 mRNA26655953
D006997Hypochlorous AcidHypochlorous Acid results in increased expression of SATB2 mRNA19376150
C492448ICG 001ICG 001 results in decreased expression of SATB2 mRNA26191083
C544151jinfukang[Cisplatin co-treated with jinfukang] results in decreased expression of SATB2 mRNA27392435
C544151jinfukangjinfukang results in decreased expression of SATB2 mRNA27392435
D007649KetamineKetamine results in decreased expression of SATB2 mRNA20080153
D007854LeadLead results in increased expression of SATB2 mRNA19921347
C042720mercuric bromidemercuric bromide results in decreased expression of SATB2 mRNA26272509
C042720mercuric bromide"[NOG protein co-treated with mercuric bromide co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of SATB2 mRNA"27188386
D008741Methyl MethanesulfonateMethyl Methanesulfonate results in increased expression of SATB2 mRNA26011545
D018817N-Methyl-3,4-methylenedioxyamphetamine"N-Methyl-3,4-methylenedioxyamphetamine results in increased expression of SATB2 mRNA"20188158
D008942MitoxantroneSATB2 protein affects the susceptibility to Mitoxantrone16217747
D009532NickelNickel results in increased expression of SATB2 protein26780400
C028007nickel monoxidenickel monoxide results in decreased expression of SATB2 mRNA19167457
C029938nickel sulfatenickel sulfate results in increased expression of SATB2 mRNA22714537
C410127PCB 180"[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in increased expression of SATB2 mRNA"25510870
C027373potassium chromate(VI)potassium chromate(VI) results in increased expression of SATB2 mRNA22714537
D011441PropylthiouracilPropylthiouracil results in increased expression of SATB2 mRNA24780913
D011794QuercetinQuercetin results in decreased expression of SATB2 mRNA21632981
D012906SmokeSmoke results in increased expression of SATB2 mRNA21095227
C017947sodium arsenitesodium arsenite affects the methylation of SATB2 gene28589171
C017947sodium arsenitesodium arsenite results in increased expression of SATB2 mRNA22714537
D053260SootSoot results in increased expression of SATB2 mRNA26551751
D013749TetrachlorodibenzodioxinTetrachlorodibenzodioxin results in decreased expression of SATB2 mRNA20106945|2163298
D013749TetrachlorodibenzodioxinTetrachlorodibenzodioxin results in increased expression of SATB2 mRNA27913140
D013749TetrachlorodibenzodioxinTetrachlorodibenzodioxin results in increased expression of SATB2 mRNA24058054
C012589trichostatin Atrichostatin A results in increased expression of SATB2 mRNA24935251
D014635Valproic Acid"[NOG protein co-treated with Valproic Acid co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SATB2 mRNA"27188386
D014635Valproic AcidValproic Acid affects the expression of SATB2 mRNA25979313
D014635Valproic AcidValproic Acid results in increased expression of SATB2 mRNA23179753|2438349
D014635Valproic AcidValproic Acid results in increased methylation of SATB2 gene29154799
D014638VanadatesVanadates results in increased expression of SATB2 mRNA22714537
D019287Zinc SulfateZinc Sulfate results in decreased expression of SATB2 mRNA27215404

GO/Pathway

GO ID GO Term Qualifier Evidence PubMed
GO:0000978RNA polymerase II proximal promoter sequence-specific DNA binding-IEA-  
GO:0000981RNA polymerase II transcription factor activity, sequence-specific DNA binding-ISA-  
GO:0000981RNA polymerase II transcription factor activity, sequence-specific DNA binding-ISM19274049  
GO:0000981RNA polymerase II transcription factor activity, sequence-specific DNA binding-NAS19274049  
GO:0001077transcriptional activator activity, RNA polymerase II proximal promoter sequence-specific DNA binding-IEA-  
GO:0003682chromatin binding-IEA-  
GO:0005515protein binding-IPI20829881  25416956  
GO:0043565sequence-specific DNA binding-IBA21873635  
GO ID GO Term Qualifier Evidence PubMed
GO:0000122negative regulation of transcription by RNA polymerase II-IEA-  
GO:0001764neuron migration-IEA-  
GO:0002076osteoblast development-IEA-  
GO:0006338chromatin remodeling-IEA-  
GO:0006357regulation of transcription by RNA polymerase II-IBA21873635  
GO:0006366transcription by RNA polymerase II-IEA-  
GO:0009880embryonic pattern specification-IEA-  
GO:0021902commitment of neuronal cell to specific neuron type in forebrain-IEA-  
GO:0045944positive regulation of transcription by RNA polymerase II-IEA-  
GO:0048704embryonic skeletal system morphogenesis-IEA-  
GO:0051216cartilage development-IEA-  
GO:0060021roof of mouth development-IEA-  
GO:0071310cellular response to organic substance-IEA-  
GO ID GO Term Qualifier Evidence PubMed
GO:0000118histone deacetylase complex-IEA-  
GO:0005634nucleus-IBA21873635  
GO:0005654nucleoplasm-IDA-  
GO:0005654nucleoplasm-TAS-  
GO:0005667transcription factor complex-IEA-  
GO:0016363nuclear matrix-IEA-  
KEGG ID KEGG Term
Reactome ID Reactome Term Evidence
R-HSA-212436Generic Transcription PathwayIEA
R-HSA-2990846SUMOylationTAS
R-HSA-3108232SUMO E3 ligases SUMOylate target proteinsTAS
R-HSA-392499Metabolism of proteinsTAS
R-HSA-4551638SUMOylation of chromatin organization proteinsTAS
R-HSA-597592Post-translational protein modificationTAS
R-HSA-73857RNA Polymerase II TranscriptionIEA
R-HSA-74160Gene expression (Transcription)IEA
R-HSA-8878166Transcriptional regulation by RUNX2IEA
R-HSA-8940973RUNX2 regulates osteoblast differentiationIEA
R-HSA-8941326RUNX2 regulates bone developmentIEA

Interactions (STRING v10.5, Interaction Score >= 0.400)

Publications (Co-occurrence of gene symbol strings and ANCO-Dependence terms)

PMID Title (Year) Author Journal
27996298Genetic Interactions in Nonsyndromic Orofacial Clefts in Europe-EUROCRAN Study. (2017 Nov)Mossey PACleft Palate Craniofac J
27258560The Role of SATB2 as a Diagnostic Marker of Sinonasal Intestinal-type Adenocarcinoma. (2018 Feb)Skalova AAppl Immunohistochem Mol Morphol